Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Accretion Pharmaceuticals Ltd

ACCPL.NS ✓ COMPLIANTFree checks used up today ☆ Track — members

NSE · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$2.03

▲ +1.68%

Market Cap $22.42M · Vol 4.80K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

21.38

FWD: N/A

Market Cap

$22.42M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

34.84

Momentum

Beta

N/A

vs Market

52W High

$2.31

11.54% below

52W Low

$0.56

234.52% above

Volume

4.80K

Avg 19.40K

P/B

1.29

Price-to-book

ROE

N/A

Return on equity

Free Float

N/A

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Accretion Pharmaceuticals Ltd (ACCPL.NS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACCPL.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.39%

-10.14%

+24.24%

+160.55%

YTD

+119.92%

+229.13%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$9.59M
Net Income	$1.03M
Revenue Growth (YoY)	N/A
Gross Margin	25.96%
Operating Margin	15.36%
Net Profit Margin	10.79%
ROE	N/A
ROA · ROIC	22.45% · 21.19%

P/E Ratio	21.38
Forward P/E (FY1)	N/A
PEG Ratio	0.15
P/S	0.76
P/B	1.29
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	11.12M

Technical Indicators

50-Day SMA	$2.09
200-Day SMA	$1.33
RSI (14)	34.84
Beta	N/A
52-Week High	$2.31
52-Week Low	$0.56

Volume Today	4.80K
Avg Daily Volume (30D)	19.40K
Relative Volume	0.25x
Volatility (10D)	55.13
Volatility (30D)	46.82
Free Float	N/A

Analyst Consensus

N/A

Current Price $2.03

Mean Target N/A

52W Low$0.56 52W High$2.31

Current

Target

$0.56 $2.31

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE

FIGIBBG01TYJ6RJ0

ISININE0T8T01010

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Company -1.36% JNJ Johnson & Johnson -5.73% ABBV AbbVie Inc. -2.40% NVS Novartis AG -0.99% NOVN.S Novartis AG -0.55%

Company Profile

Accretion Pharmaceuticals Limited is an India-based company. The Company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of drugs, pharmaceutical products and related products. Its product portfolio includes five verticals, such as tablet, oral liquid, external preparation, capsule, and oral powder. Its products include Azithromycin 250 mg/500 mg, Ciprofloxacin 250/500 mg, Ketoconazole 200 mg, Levofloxacin 250mg/500 mg, Levofloxacin 250 mg+Ornidazole 500 mg, Itraconazole 100mg/200 mg (AS PELLETS), Ofloxacin 100mg + Metronidazole 200mg suspension, Aceclofenac 100mg+Paracetamol 325 mg, Deflazacort 6 mg, Ibuprofen 400mg/600mg, Mefenamic acid 250mg+Dicyclomine HCL 10mg, Nimesulide MD 100mg, Doxofylline 400 mg, Ibuprofen 100mg oral suspension, Montelukast 5mg/10mg, Cetirizine dihydrochloride 5mg/10mg, Omeprazole 20mg, Ondansetron 2 mg Syrup, and others.